Stryker Heiress Trims SYK; Family Trust at 51% Portfolio

Ronda E. Stryker — granddaughter of Stryker Corporation founder Homer Stryker and one of the largest family shareholders of the medical-device maker — filed a Form 4 in early February covering a block of open-market sales executed on February 4 and February 5, 2026 at prices between $361.50 and $368.56. The transactions totaled approximately $91.7 million across 8 lots of varying size. The cumulative Form 4 sell ledger across Ronda Stryker's filing history now stands at $1.85 billion across 1,431 transactions. The headline read is straightforward — a founder-family insider monetizing during a price rally to a then-near-all-time-high above $360. The deeper read sits in the family-trust 13D filings, which show the Stryker family concentration remains structurally intact.

Schedule 13D/A filed on April 14, 2026 reports Ronda E. Stryker at 4.00% beneficial ownership — approximately 15.2 million shares of Stryker Corp.. Greenleaf Trust, the Stryker family's trust company that holds significant family shares across multiple vehicles, files separately at 4.40% beneficial ownership at 16.8 million shares — and Greenleaf's 13F (not 13D) shows the trust running SYK at 51.45% of its entire reported portfolio. The family is not exiting Stryker. The family is doing periodic Form 4 monetization at favorable prices while continuing to hold a concentrated structural position through the family trust.

What the February 2026 sales actually were

The granular price tiers — $361.50, $362.42, $363.34, $364.29, $365.26, $366.35, $366.99, $368.56 — and the lot sizes (2,160 to 68,688 shares) are the algorithmic-execution fingerprint of a broker filling against a Rule 10b5-1 plan. Stryker family insiders have run plan-based monetization schedules across multiple years; the February cadence is consistent with plan execution rather than discretionary timing.

The combined Feb 4-5 transaction sold approximately 252,000 shares at a weighted-average price near $364, generating roughly $91.7 million of proceeds. After the sale, Ronda Stryker holds 2,207,331 direct shares per Form 4 Table I plus the additional beneficial-ownership exposure reported on Schedule 13D/A.

SYK's price action through early 2026 saw the stock climb from $340 in early January to $370+ by mid-February. The plan execution captured the leg-up effectively — broker-algorithmic execution at the top decile of the price range.

The Greenleaf Trust 51.45% concentration

The institutional 13F holder table for SYK shows the standard index sleeve at the top (BlackRock at $9.07B / 0.16% portfolio, Vanguard Capital at $7.35B / 0.18%, State Street at $5.37B / 0.18%). The unusual line is Greenleaf Trust at $5.24 billion and 51.45% of portfolio. No mainstream active manager runs a single-name concentration of 51%. This is a family-office trust holding SYK as the dominant inherited asset — Greenleaf is essentially a single-stock concentration vehicle for the Stryker family's surplus capital above other diversification.

For comparison, our recent batch covered State Farm Mutual's 8.13% top position in Caterpillar — the highest single-name concentration we documented for a $100+ billion P&C insurance balance sheet. Greenleaf's 51.45% in SYK is six times that, because Greenleaf is not a diversified institutional balance sheet; it is a family-office trust designed to hold concentrated founder-family wealth in the founding company's stock.

The other active conviction layer

Strip out the index sleeve and the family-trust layer, and active discretionary conviction in SYK sits with:

• AllianceBernstein L.P.: $2.26 billion at 0.72% portfolio. AllianceBernstein runs $317 billion across active equity and fixed-income strategies. A 0.72% portfolio weight on SYK is roughly 2x the S&P 500 index weight of ~0.40% — meaningful active overweight from one of the largest US asset managers.
• Wellington Management Group: $2.28 billion, 0.40% portfolio — slight overweight.
• JPMorgan Chase & Co.: $5.09 billion, 0.33% portfolio — index weight or slight underweight.

AllianceBernstein's 0.72% portfolio weight is the cleanest discretionary active call. The position has been steady across recent quarters — AB's medical-device team appears to view SYK as a structural compounder with multi-year growth visibility in surgical-instrument and joint-reconstruction markets.

What 'owns zero shares' would mean (and why it's wrong here)

Ronda Stryker's Form 4 Table I summary reports 2,207,331 shares after the February sale. This is direct, non-derivative-only Class A common. The 13D/A simultaneously reports her at 4.00% beneficial ownership of approximately 15.2 million shares. The discrepancy reflects shares held indirectly — through family limited partnerships, generation-skipping trusts, and other estate-planning vehicles that aggregate into beneficial ownership for Section 16(b) purposes but not into the direct-holdings summary on Form 4 Table I.

If you read only the Form 4 cover summary, you would conclude Ronda Stryker holds 2.2 million shares. The Schedule 13D/A correction lifts that to 15.2 million shares. Layered with Greenleaf Trust's separate 16.8 million share position (also Stryker family-controlled), the Stryker family's combined beneficial ownership of SYK is approximately 32+ million shares, or roughly 8% of total Stryker Corporation outstanding stock. The family remains the single largest blockholder group.

What to watch

1. Stryker Q2 2026 earnings (late July). Trauma and Extremities revenue growth and joint-reconstruction inventory trends will determine whether the price action above $360 sustains.
2. The May 8 Form 4. The discover script flagged a May 8 transaction that did not appear in the recent activity snapshot. Watch Ronda E. Stryker's filing history for the latest filings to see if the cadence continued through Q2.
3. AllianceBernstein's Q2 2026 13F (due August 14, 2026). Whether AB's 0.72% portfolio weight on SYK holds or expands is the cleanest non-family active conviction signal. Track via the institutional signals feed.
4. Greenleaf Trust's Q2 2026 13F. The 51.45% portfolio weight on SYK is structural family-trust concentration. A material trim would signal estate-planning rebalancing, which is rare but high-information when it happens.

Ronda Stryker's February sales monetized $91.7 million at favorable prices. The cumulative $1.85 billion Form 4 ledger does not represent a family exit — Schedule 13D/A and Greenleaf Trust's 51.45% portfolio concentration confirm the family is still the dominant blockholder of SYK by a wide margin. For a primer on reading Form 4 Table I summaries alongside Schedule 13D beneficial ownership disclosures, see our explainer hub.

Source: SEC Form 4 filings dated 2026-02-04 and 2026-02-05, Schedule 13D/A filed 2026-04-14, accession listings at EDGAR — Stryker Ronda E filer index.